Multiple publications and editorials discuss RESHAPE-HF2 and other RCTs on MTEER for SMR. https://t.co/r1WrB6e3lT https://t.co/kSxFLJPT7l https://t.co/2mmFEjepk5 More clarity needed from trials with call for individual patient–level meta-analysis! MR quantitation remains

A quick recap of new randomized trials in the fields of coronary and valvular interventions you may have missed this year at #EuroPCR if you were only watching live cases or attending practical sessions.

Everything we have learned so far about the revascularization of non-culprit lesions in patients with acute myocardial infarction and multivessel disease... in 1 minute.

You may have noticed a 🆕 feature on EuroIntervention🤫. We are proud to unveil Cory, a new AI assistant! This cutting-edge tool available to subscribers is here to enhance your reading experience by offering deeper insights & a better understanding of complex topics. Enjoy it!

Dr. @rajivxgulati, et al offer a collection of observations that support an alternate hypothesis in many cases—that #SCAD is a secondary event instigated by SICM (Takotsubo and variants). Learn more here: https://t.co/K3GCQIpS78 #JACCAdvances #cvCAD

Tonight I lost my Personal Hero, my Father, Jorge Roberto Buchler, M.D. p.H.D. He passed peacefully and surrounded by his family and friends after a long battle with Intersticial Lung Disease. He Was an excepcional Husband, Father, Grandfather and Interventional Cardiologist 🧶

In this meta-analysis of 26 RCTs we found a favorable effect of thrombus aspiration on post-infarction LV remodeling, ultimately influenced by mean ischemic time, target vessel and device employed. Available online on #IJC

👍Coronary Wires, Guide Extenders, Microcatheters etc: Comparisons🤜🤛…

#TCT2023 Pat w LVEF <50% and FFR less than ∼0.75 or w stenoses 90%-99% will demonstrate an improvement in LVEF with PCI. Those with FFR >∼0.75 or with angiographic stenoses <70% are unlikely to benefit. Resting indices appear unable to predict improvement in LVEF.

Among patients with MI and FFR-negative nonculprit lesions, presence of OCT-defined high-risk plaques is associated with worse clinical outcome, which is mainly driven by higher number of unplanned revascularizations https://t.co/bLTGjwF6Y4 @JAMACardio

Apple Watch can produce reliable 9-lead ECG (I,II,III,V1-6). With proper patient education, multi-lead ECG's at home can provide additional clinical data. #cardiotwitter Using the Apple Watch to Record Multiple-Lead Electrocardiograms in Detecting Myocardial Infarction: Where

We performed an updated NMA comparing IVUS, OCT, and CA in PCI (6 yrs after the last NMA). Topic inspired by #SCAI2022. Included 28 RCTs and only RCTs. Check out our paper for results: https://t.co/CgbEeUbN8T Special thank you to @VijAviral @MichaelGNanna @SVRaoMD @SteveAChicago

Another successful story of #wooshing…large RA thrombus in transit through a persistant foramen ovale - catch me if you can! #CardioTwitter #innovation @mmamas1973 @mirvatalasnag @Steph_Achenbach @KardiologieHH @dscharpfMD

Outcomes of Medical Therapy Plus PCI for Multivessel or Left Main CAD Ineligible for Surgery: @JACCJournals Agree with the results: this is what we see in practice 4-point Summary below... 👇👇👇

1/4: Patients with left main and/or multivessel CAD at prohibitive surgical risk pose a clinical dilemma due to complex coexisting illness, frailty, and complex anatomy. Few data exist to inform guidelines for their treatment, given their absent representation in prior trials.

2/4: The OPTIMUM registry is a prospective, multicenter study designed to examine clinical decision-making, contemporary management, and the clinical and health status outcomes of these challenging patients.

#transiliac #tavr #tavi #interventionalcardiology #chimneystent #structural #CardioTwitter #aorticstenosis @andrebrq @AdrianoT @valenteTC

Check out the 3D RIGHT guide catheter for RCA interventions. Great for routine and complex RCA interventions from radial access

1/⚡️How to assess tricuspid valve by TOE #echofirst? ➡️What's the role of X-plane? ➡️How to get the best 3D image? ➡️Tips and tricks about transgastric view ➡️What we need to know about pacemaker lead Take a look this thread 🧵 @NMerke @iamritu @hahn_rt @denisamuraru @lpbadano

Imagine we invented an infusion to be given during PCI (SUVI infusion) which would take 20min, cost a few hundred dollars per case and be virtually free of side effects. Imagine SUVI infusion RCTs with 2.5k patients showed a HR of 0.43 for death at 3 years. Follow me below…